Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Sopheon Terug naar discussie overzicht

Sopheon januari 2022

25 Posts
Pagina: 1 2 »» | Laatste | Omlaag ↓
  2. Gartje 31 december 2021 18:01

    • Gartje

      Lid sinds: 26 aug 2016

      Laatste bezoek: 23 feb 2024

    • Aanbevelingen

      Ontvangen: 56

      Gegeven: 1

    •    Aantal posts: 955

    Hier sluit ik me bij aan, en dan nog eens een succesvol 2022 voor ons Sopheon aandeelhouders er bij.
  3. abc123xyz987 31 december 2021 18:35

    • abc123xyz987

      Lid sinds: 14 jul 2008

      Laatste bezoek: 17 apr 2024

    • Aanbevelingen

      Ontvangen: 42

      Gegeven: 2

    •    Aantal posts: 245

    quote:

    marblesthegame schreef op 31 december 2021 09:11:

    Iedereen een gezond en mooi jaar gewenst.
    Jij en iedereen hier op het forum een gezond en mooi jaar gewenst en dat 2022 ons Sopheon mag worden.

    Groet ABC
  8. marblesthegame 17 januari 2022 20:12

    • marblesthegame

      Lid sinds: 06 jul 2005

      Laatste bezoek: 28 apr 2024

    • Aanbevelingen

      Ontvangen: 355

      Gegeven: 722

    •    Aantal posts: 1.442

    Sopheon PLC
    Issue of Equity

    RNS Number : 7129Y
    Sopheon PLC
    17 January 2022

    For immediate release

    SOPHEON PLC
    ("Sopheon" or the "Company")

    Issue of Equity - Option Exercise

    Sopheon, the international provider of software and services for Enterprise Innovation Management solutions, announces that, following the exercise of options by certain employees, it has allotted 41,109 new Ordinary Shares of 20 pence each in the Company ("Ordinary Shares"). Application will be made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 21 January 2022.


    The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares. The total number of Ordinary Shares in issue following Admission will be 10,553,325. The Company does not hold any shares in treasury. Accordingly, the figure of 10,553,325 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
  11. Gartje 22 januari 2022 13:32

    • Gartje

      Lid sinds: 26 aug 2016

      Laatste bezoek: 23 feb 2024

    • Aanbevelingen

      Ontvangen: 56

      Gegeven: 1

    •    Aantal posts: 955

    Vorig jaar de 25ste de trading update, ben benieuwd of we woensdag wat meer horen, het is uiterst stil!!!
  14. Bertus S 25 januari 2022 08:12

    • Bertus S

      Lid sinds: 03 aug 2002

      Laatste bezoek: 19 feb 2024

    • Aanbevelingen

      Ontvangen: 4534

      Gegeven: 3919

    •    Aantal posts: 27.083

    Trading Update

    Sopheon, the international provider of software and services for Enterprise Innovation Management solutions, is pleased to provide the following trading update for the year ended 31 December 2021.

    On 20 December 2021 we reported our acquisition of the ROI Blueprints (“ROIB”) business, along with a statement that financial performance would be comfortably in line with market expectations. We are now delighted to report that we expect that revenue for the year ended 31 December 2021 will exceed $34m (2020: $30m). Annual Recurring Revenue (“ARR”) at the end of 2021 is expected to exceed $20.5m (2020: $18m), a performance we are pleased with. This, coupled with contracted consulting services, means that revenue visibility1 for 2022 has grown to approximately $23.4m (2020: $22.0m).

    Adjusted EBITDA is expected to exceed $6m (2020: $5.9m). Net cash on 31 December 2021 was $24.1m (2020: $21.6m) after funding the initial payment on the ROI Blueprints acquisition, demonstrating the cash generative nature and resilient cash performance of the business and underlining our robust balance sheet. In addition to the revenue out-performance, the profit result was assisted by the deferral of some of our anticipated investment plans, in particular in the staffing of product development. Like many other software businesses, we face ongoing challenges in recruiting technical staff. However, as noted in previous announcements, along with the appointment of Greg Coticchia as CEO in April, we have added new leadership in sales, marketing and product areas and expanded resources in 2021. We have increased the pace of Accolade product releases, and also expanded a number of marketing initiatives to build the Sopheon profile, and grow the pipeline. This includes programs to introduce the ROIB solution to our customer base later this month. Several cross-sell opportunities have been identified, and the ROIB team is already fully integrated at Sopheon. Our growth initiatives will continue and accelerate in 2022.

    The improvement in ARR underlines continued traction in our migration to a Software as a Service (“SaaS”) recurring revenue model, giving both enhanced revenue visibility to future periods and improved quality of earnings. Approximately 50% of more than 70 license transactions signed during 2021 were for SaaS contracts. Moreover, the value of SaaS bookings was more than double that of perpetual contracts. This includes another six existing customers converting from the perpetual model to a SaaS model. Gross retention of ARR returned to our normal strong levels, at 95% compared to 91.5% during the challenging conditions of 2020.

    Financial expectations noted above are preliminary, and subject to year-end financial close and audit review processes. In line with our normal reporting schedule, Sopheon plans to issue its results for the year ended 31 December 2021 on 24 March 2022.

    Sopheon’s Chairman, Andy Michuda said: “As I noted in our December announcement, it was great to end the year with our first acquisition for some time, coupled with strong execution in the core business. We continue to explore and evaluate further M&A opportunities. In parallel, we are also advancing nicely on our stated transition towards a SaaS business, both operationally as well as financially, intended to enhance predictability, quality of earnings and overall shareholder return. I am encouraged with the foundational progress Greg and the team have made in 2021 and look forward to further positive developments as the new year progresses.”

    For further information contact:

    Andy Michuda (Chairman)
    Arif Karimjee (CFO) Sopheon plc + 44 (0) 1276 919 560

    www.sopheon.com/financial-releases/tr...

    Bertus S.
  16. Gartje 25 januari 2022 09:24

    • Gartje

      Lid sinds: 26 aug 2016

      Laatste bezoek: 23 feb 2024

    • Aanbevelingen

      Ontvangen: 56

      Gegeven: 1

    •    Aantal posts: 955

    In ieder geval geen lijken uit de kast, maar ook geen raket die ons door die vreselijk barrière van 10 pond heen gaat drukken. Weer een jaar van achter over leunen en hopen op ooit die uitschieter!
  17. abc123xyz987 25 januari 2022 10:28

    • abc123xyz987

      Lid sinds: 14 jul 2008

      Laatste bezoek: 17 apr 2024

    • Aanbevelingen

      Ontvangen: 42

      Gegeven: 2

    •    Aantal posts: 245

    quote:

    Arie de Beuker schreef op 25 januari 2022 08:27:

    Geen verrassingen vind ik,

    Gr
    Arie de Beuker

    Omzet +14%
    ARR +13,9%
    Net cash +11%

    SAAS = saai maar ook leuk.

    Groet ABC.
  18. [verwijderd] 25 januari 2022 12:35

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Prima resultaten hoor wat mij betreft. Erg tevreden met de nieuwe wegen die Greg Coticchia en Michuda hebben ingezet.
    De 10 pond en verder is een kwestie van tijd. Zou onder de vlag van Mence allemaal nog veel langer hebben geduurd.
  19. [verwijderd] 25 januari 2022 12:40

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    vlg Finncap

    SOPHEON (SPE): CORP Positive end to 2021 leads to promising start for 2022 too After the positive December trading update accompanying the acquisition of ROI Blueprints, today’s update gives detail of 2021 outperformance in both revenue & EBITDA, with net cash at year end of $24.1m vs $21.9m, even after the acquisition. Revenue of over $34m (>+3% vs $33mE) delivered 14% growth vs FY20, and returned EBITDA over $6.0m, +35% vs. expectations and +2% vs FY20, at a margin of 18% instead of 14%E. In addition to revenue outperformance, deployment of planned increased costs was deferred by the well-known challenges to IT recruitment experienced across the industry, with positive consequences for profitability and cash (+10% vs $21.9mE) – nevertheless, the group continues to invest in sales, marketing, product & expanded resources, an increased pace of Accolade releases, and expanded market initiatives to build the pipeline. Importantly, the group’s KPIs in ARR and retention continued to demonstrate improving earnings quality, with ARR +14% at $20.5m (vs $18.0m in FY20 and $19.0m at 1H21), and 95% gross retention (vs 91.5% FY20). Combined with contracted consulting revenue due for recognition within the year, the group has once again set a record for full-year visibility by this stage of the year at a total of $23.4m (vs $22.0m at FY21). We leave forecasts unchanged, while nudging up our target price to 1250p (1200p), leaving plenty of capacity for outperformance as the world opens up during the year.
  20. [verwijderd] 25 januari 2022 12:44

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    - Sopheon has delivered FY21 forecasts ahead of expectations, echoing routine pre-COVID. Our
    target price remains based on 4.1x FY22 EV/Sales, and we expect organic growth to be
    complemented by M&A through use of the $24.1m cash, while maintaining a strong cash balance
    to reassure enterprise clients.

    - The focus for growth remains on KPIs, with the growing importance of ARR, as the percentage
    of SaaS revenue expands within the recognised revenue. Of more than 70 licence transactions
    signed in 2021 (FY20: 35, 1H21: 43 as the COVID backlog cleared), more than 50% were SaaS
    contracts, while the total value of SaaS contracts signed was double that of perpetual. Six existing
    customers (FY20: 4) converted to SaaS, heavily skewed to 1H21 (5), while retention of the
    remaining licence/maintenance customers returned to 95% (FY20: 91.5%) post the initial
    experience of lockdowns. Visibility of 2022 revenue incorporates ARR and also additional
    contracted revenue (such as consultancy) for recognition in FY22. Visibility currently stands at
    $23.4m (FY20: $22m), representing 63% of FY22 revenue expectations, comparing with 63-65%
    experienced in FY19-FY21. Outperformance has returned, having been a recurring theme for pre
    COVID Sopheon during 2016-2019, given the level of operational gearing in the model. The
    deferral of some planned spend in product development staff has added to EBITDA
    outperformance in the current year, but the group continues to treat M&A as a viable alternative
    to R&D, and to invest in sales, marketing, product, and additional resources.
25 Posts
Pagina: 1 2 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.840
AB InBev 2 5.285
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.580 46.337
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 8.898
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 31
Adomos 1 126
AdUX 2 457
Adyen 13 16.357
Aedifica 2 829
Aegon 3.257 320.053
AFC Ajax 537 7.018
Affimed NV 2 5.752
ageas 5.843 109.777
Agfa-Gevaert 13 1.856
Ahold 3.536 73.980
Air France - KLM 1.024 34.311
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.771
Alfen 12 16.275
Allfunds Group 3 1.191
Almunda Professionals (vh Novisource) 651 4.247
Alpha Pro Tech 1 17
Alphabet Inc. 1 334
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.484 114.757
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.820 240.257
AMG 965 125.714
AMS 3 73
Amsterdam Commodities 303 6.519
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 382
Antonov 22.632 153.605
Aperam 91 14.111
Apollo Alternative Assets 1 17
Apple 5 313
Arcadis 251 8.614
Arcelor Mittal 2.023 318.600
Archos 1 1
Arcona Property Fund 1 266
arGEN-X 15 9.106
Aroundtown SA 1 176
Arrowhead Research 5 9.270
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.677
ASML 1.762 76.910
ASR Nederland 18 4.122
ATAI Life Sciences 1 7
Atenor Group 1 333
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.650
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.665

Macro & Bedrijfsagenda

  1. 29 april

    1. NL producentenvertrouwen april
    2. Philips Q1-cijfers
    3. Umicore Q1-cijfers
    4. Proximus Q1-cijfers
    5. Fra BBP eerste kwartaal (voorlopig)
    6. AkzoNobel €1,54-ex-dividend
    7. Besi €2,15 ex-dividend
    8. Fugro €0,40 ex-dividend
    9. Heineken €1,04 ex-dividend
    10. Vastned €1,28 ex-dividend
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda